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 Abstract-- We have investigated a combined 2D/3D protocol 
for minimizing contamination in dual tracer P.E.T. studies in 
which the tracers are administered on a timescale that is short 
compared to the half-lives.  We have performed a series of 
phantom studies on an Advance and a Discovery ST (GE 
Healthcare Technologies), using a torso phantom with cardiac 
insert (Data Spectrum Corporation) to simulate a combined FDG 
and NH3 scan protocol for a patient with ischemia. The phantom 
was imaged in a series of alternating 2D/3D acquisitions as it 
decayed over 6 half-lives. By comparing 2D and 3D images, we 
have verified that 3D images are of comparable accuracy to 2D 
images, even with realistic out-of-field activity challenging the 3D 
scans. Based on scan and image statistical quality, we have 
recommended optimal doses for maximizing the image quality of 
both scans. 
I. INTRODUCTION 
UAL tracer P.E.T. studies suffer from contamination when 
the scans are performed on a timescale that is short 
compared to the half-lives. To minimize contamination in 
the resulting images, we have investigated a technique in 
which the first tracer is a low dose imaged in the higher-
sensitivity 3D mode, and the second tracer is a much higher 
dose imaged in the lower-sensitivity 2D mode. The specific 
protocol we investigate is a combined FDG cardiac viability 
scan (initial low dose imaged in 3D) with an N-13 ammonia 
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cardiac perfusion scan (high dose imaged in 2D) [1].  The N-
13 Ammonia injection and scan follow immediately after the 
FDG scan, with the patient remaining on the scan table.  
We have performed a series of phantom measurements, with 
the goal of optimizing the administered dose of both tracers to 
maximize the image quality of both images. 
 
 
Fig. 1.  Phantom setup, showing arms and out-of-field cylindrical phantom. 
II. METHODS 
We have performed phantom measurements using a torso 
phantom with a cardiac insert (Data Spectrum Corp). A 5.4 ml 
fillable cardiac defect inside the 110 ml myocardium was used 
to simulate both a FDG hot defect (activity in defect, non-
radioactive water in myocardium) and NH3 cold defect 
(activity in myocardium, non-radioactive water in defect) scans 
for a patient with ischemia. For each scan type, realistic 
background and liver activity concentrations were used based 
on patient data. We use an estimate for the equivalent patient 
dose of 5 times the torso-phantom activity. The torso phantom 
was aligned in the scanner field of view, with one liter saline 
bottles (no activity) simulating arms. A separate 6 liter 
cylindrical phantom was placed near the phantom to provide 
out-of-field activity. 
For each configuration (hot and cold defect) the torso 
phantom was imaged in a series of alternating 2D/3D 2 min 
acquisitions as it decayed from an initial activity of 560 MBq 
of F-18 (with an additional 560 MBq out-of-field activity in 
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 the cylindrical phantom) for 6.2 half-lives. Data were acquired 
on an Advance [2] and a Discovery ST [3] (GE Healthcare 
Technologies). All scans were reconstructed using filtered 
back projection due to its linearity. 
From each image in the decay series, we acquired scan 
statistics (i.e., prompt and delayed counts), as well as  region 
of interest (ROI) values for ~30 myocardium and ~30 
background  ROI’s. 
A. 2D and 3D Accuracy 
To justify the combination of 2D and 3D scans in a single 
protocol, we first need to verify accuracy of the 3D images. To 
do this, we began by forming reduced-noise images by 
averaging five two-minute images. From these reduced-noise 
images, we extracted myocardial and background ROI’s from 
both the 2D and 3D image sets. Taking the low-dose 2D 
images as the standard, we performed a region-by region 
comparison with the 3D images by dividing each 3D ROI 
value from a given slice by the average 2D ROI value from the 
same image slice.  We expect these normalized ROI values to 
have a value near one for good 2D/3D agreement.  
Because we are proposing to use a high dose for the 2D 
scan, we also need to verify that scanner performance in 2D 
does not degrade at high activity levels. To do this, we 
compared the average value of 30 2D myocardial ROI’s as a 
function of activity, to a linear fit. 
B. Evaluating Scan and Image Statistical Quality. 
Using the scan statistics (prompt and delayed counts) we 
calculated an estimate of statistical quality for both the FDG-
like scan and the contaminated NH3 scan as a function of 
activity. 
In the clinical protocol, the FDG scan is completed before 
the NH3 is administered, and therfore it is uncontaminated. We 
can therefore model it with the hot defect scan data alone. We 
used the true and prompt counts from the hot defect scans to 
derive noise equivalent count rate (NEC) [4] curves as a 
function of activity.   
To calculate statistical quality for an NH3 scan contaminated 
with a small amount of residual FDG, we must combine data 
from the cold defect scan and the hot defect scan. For the case, 
in which the 3D FDG scan has been subtracted from the 2D 
NH3 scan, the true counts that contribute to the signal come 
only from the cold defect scan, whereas the true and the 
prompt counts from both cold and hot defect scans contribute 
noise. Knowing this, we can derive an NEC-like estimate of 








= , (1) 
where T and P are the true and prompt counts from the hot 
and cold defect scans, and the factors of two in the 
denominator account for the additional noise added when 
subtracting the FDG image from the contaminated NH3 image. 
If the FDG image is not subtracted from the contaminated NH3 
image, we do not have the additional noise introduced by the 
subtraction. However, the true counts in the FDG scan reduce 









.  (2) 
For all cases we considered, we found that the improvement 
in contrast outweighed the increased noise. The rest of this 
paper will focus on this case.  
To calculate image signal to noise ratio (SNR) for the FDG 
scan, we take the signal to be the difference between the  
average of the 30 hot myocardial ROI’s and the average value 
of the background ROI’s, and the noise to be the standard 
deviation of the background ROI’s.    
For the contaminated NH3 image, we again must combine 
data from the hot and cold defect scans. For the case where the 








=  (3) 
Where Scold is the difference between the average 
myocardial ROI value and the background, and σcold and σhot 
are the standard deviations of the cold and hot defect 
background ROI’s respectively. 
III. RESULTS 
A. 2D and 3D Accuracy 
Figures 2 and 3 show results for the comparison of 2D and 
3D accuracy. In fig. 2, we show a representative reduced-noise 
2D and 3D image, and the subtracted image. Profiles through 
the images confirm that regional differences are small 
compared to image noise.   
 
2D 3D Difference  
Fig. 2.  Low-noise 2D and 3D images, and their difference for the Discovery 
ST.  
 
Fig. 3 shows the ratio of several 3D myocardial ROI’s and 
one 3D background ROI, all from the same randomly chosen 
image slice, to the average 2D ROI value from the same slice.   
The close agreement with the average 2D value, and the 
relatively small deviation in the individual 3D ROI values over 
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Fig. 3.  ROI values for four 3D myocardial ROI’s and one background ROI, 
normalized to the average 2D ROI value.  (Discovery ST) 
 
In Fig. 4, we compare the average 2D myocardial ROI value 
as a function of activity to a linear fit. That the 2D ROI values 
remain linear with activity up to at least 2500 MBq validates 
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Fig. 4.  Average 2D ROI value as a function of activity, compared with a linear 
fit. 
B. Evaluating Scan Statistical Quality. 
Figures 5 and 6 show scan statistical quality for the FDG-
like hot defect and the contaminated NH3 cold defect scans for 
the Discovery ST.  For the NH3 scan, we show curves for 
several values of FDG dose. The top-most curve represents the 
limit of no FDG contamination, and is equivalent to the 2D 
NEC. We see that increasing FDG dose decreases scan 






























































Fig. 6.  Contaminated NH3 scan statistical Quality vs. Activity for the 
Discovery ST. 
 
Figures 7 and 8 show image SNR for the Discovery ST. We 
find that, although increasing FDG dose decreases the quality 
of the contaminated NH3 scan, there is a point of diminishing 
returns, beyond which there is little further gain in SNR, even 




























Fig. 7. Image Signal to Noise vs. equivalent patient activity for the DST hot 
defect scan 





































Fig. 8.  Image Signal to Noise vs. equivalent patient activity for the 
contaminated DST cold defect scan.   
 
This point corresponds to an FDG dose of ~ 300 MBq 
(Discovery ST) and ~ 200 MBq (Advance). For both scanners, 
the peak SNR occurs at a dose of ~ 1850 MBq of NH3. 
IV. CONCLUSIONS 
We have used a series of phantom studies to investigate a 
combined 2D/3D imaging protocol designed to maximize 
image quality in dual tracer PET studies.  We have verified 
that the 3D images are of comparable accuracy to the 2D 
images, even though we added significant out-of-field activity, 
and that scanner performance remains linear for large 2D 
doses. By combining data from hot and cold defect scans, we 
have been able to calculate the statistical scan quality and SNR 
for both the FDG-like scan and the contaminated NH3 scan. 
Based on these calculations, we have made specific dose 
recommendations for optimizing the image quality of both 
scans. At these doses, the total whole body radiation dose [5] 
from both injections is equivalent to that of a  440 MBq FDG 
injection (Discovery ST) and a 330 MBq FDG injection 
(Advance). 
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